Skip to main content
Evidence Snapshot

Aldo-keto reductase family 1 member B1

CHEMBL2622 SINGLE PROTEIN Rattus norvegicus
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T05:40:02Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2622
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Aldo-keto reductase family 1 member B1 as ChEMBL target CHEMBL2622, mapped to UniProt P07943. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Aldo-keto reductase family 1 member B1
SINGLE PROTEIN · Rattus norvegicus
As of 2026-09-13
ChEMBL target ID
CHEMBL2622
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P07943
Aldo-keto reductase family 1 member B1
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Aldo-keto reductase family 1 member B1 matters

As of 2026-09-13

Aldo-keto reductase family 1 member B1 is reviewed as Aldo-keto reductase family 1 member B1 (UniProt P07943); the current evidence base includes 15 approved drugs, 2129 compounds, and 274 assays, with lead potency reaching pChEMBL 9.4.

Protein context
Aldo-keto reductase family 1 member B1

Aldo-keto reductase family 1 member B1 Sequence length is 316 aa.

Review this target as Aldo-keto reductase family 1 member B1, mapped to UniProt P07943. Sequence length is 316 aa.

Protein source · UniProt accession via ChEMBL component mapping
UniProt P07943 Protein
Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 15 approved drugs, 2129 compounds, and 274 assays for this target. The dominant activity type is IC50. CHEMBL269550 is the current potency anchor at pChEMBL 9.4.

Use CHEMBL269550 as the tractability anchor when discussing potency (pChEMBL 9.4).

Activity source · ChEMBL 36 via Core Engine
15 approved pChEMBL 9.4
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Aldo-keto reductase family 1 member B1 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P07943, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

2129
Total Compounds
274
Total Assays
15
Approved Drugs
IC50: 2214.0, KI: 841.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL269550
 9.4 IC50 —
No preferred name
CHEMBL2261578
 8.9 IC50 —
No preferred name
CHEMBL436
 8.7 IC50 Approved
No preferred name
CHEMBL138065
 8.6 IC50 —
No preferred name
CHEMBL2261575
 8.4 IC50 —

Approved Drugs

Structure Compound First Approval
EPALRESTAT
CHEMBL56337
 1992
TOLRESTAT
CHEMBL436
 1989
TANNIC ACID
CHEMBL506247
 1982
SULINDAC
CHEMBL15770
 1978
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T05:40:02Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2622